SCHEMBL13520171

SCHEMBL13520171

CC1C[C@H](NC(=O)OC(C)(C)C)CN(Cc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
JAK1 P23458 1/20 0.47
KDM1A O60341 1/20 0.46
MAOB P27338 1/20 0.46
EPHX2 P34913 1/20 0.46
KCNA3 P22001 1/20 0.45
DRD2 P14416 4/20 0.43
NPFFR1 Q9GZQ6 1/20 0.43
NPFFR2 Q9Y5X5 1/20 0.43
MEN1 O00255 1/20 0.42
MCHR1 Q99705 1/20 0.42
FUCA1 P04066 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
EIF2AK4 Q9P2K8 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
NAMPT P43490 1/20 0.41
CCR5 P51681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552482 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL19051699 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL30404117 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL1552484 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL2378151 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL9929564 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL17304781 0.93 KMT2A (0.65) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL1815532 0.90 KMT2A (0.65) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL25263326 0.88 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL21166304 0.88 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010002415-A1 TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2010-01-07 WO disclosed
WO-2010002965-A2 PNEUMONIA TREATMENT TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2010-01-07 WO disclosed
WO-2009023473-A2 ANTIMICROBIAL PARENTERAL FORMULATION TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-02-19 WO disclosed
US-20090042932-A1 ANTIMICROBIAL PARENTERAL FORMULATION TAIGEN BIOTECHNOLOGY COMPANY LTD. (TW) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042932-A1 ANTIMICROBIAL PARENTERAL FORMULATION SLC10A2, ABCB11, SLC47A1 KMT2A 4823/4885L3MBTL1 3571/4885JAK1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.